Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Depression Treatment Pipeline Review H2 2016

Wednesday, October 19, 2016 23:08
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Depression – Pipeline Review, H2 2016’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693292-depression-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Depression 
- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects 
- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Depression 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693292-depression-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
Introduction 8 
Depression Overview 9 
Therapeutics Development 10 
Depression – Therapeutics under Development by Companies 12 
Depression – Therapeutics under Investigation by Universities/Institutes 20 
Depression – Pipeline Products Glance 22 
Depression – Products under Development by Companies 26 
Depression – Products under Investigation by Universities/Institutes 37 
Depression – Companies Involved in Therapeutics Development 39 
Depression – Therapeutics Assessment 131 
Drug Profiles 151 
Depression – Dormant Projects 432 
Depression – Discontinued Products 457 
Depression – Product Development Milestones 465 
Appendix 474

List of Tables 
Number of Products under Development for Depression, H2 2016 29 
Number of Products under Development for Depression – Comparative Analysis, H2 2016 30 
Number of Products under Development by Companies, H2 2016 32 
Number of Products under Development by Companies, H2 2016 (Contd..1) 33 
Number of Products under Development by Companies, H2 2016 (Contd..2) 34 
Number of Products under Development by Companies, H2 2016 (Contd..3) 35 
Number of Products under Development by Companies, H2 2016 (Contd..4) 36 
Number of Products under Development by Companies, H2 2016 (Contd..5) 37 
Number of Products under Development by Companies, H2 2016 (Contd..6) 38 
Number of Products under Investigation by Universities/Institutes, H2 2016 40 
Comparative Analysis by Late Stage Development, H2 2016 41 
Comparative Analysis by Clinical Stage Development, H2 2016 42 
Comparative Analysis by Early Stage Development, H2 2016 43 
Comparative Analysis by Unknown Stage Development, H2 2016 44 
Products under Development by Companies, H2 2016 45 
Products under Development by Companies, H2 2016 (Contd..1) 46 
Products under Development by Companies, H2 2016 (Contd..2) 47 
Products under Development by Companies, H2 2016 (Contd..3) 48 
Products under Development by Companies, H2 2016 (Contd..4) 49 
Products under Development by Companies, H2 2016 (Contd..5) 50 
Products under Development by Companies, H2 2016 (Contd..6) 51 
Products under Development by Companies, H2 2016 (Contd..7) 52 
Products under Development by Companies, H2 2016 (Contd..8) 53 
Products under Development by Companies, H2 2016 (Contd..9) 54 
Products under Development by Companies, H2 2016 (Contd..10) 55 
Products under Investigation by Universities/Institutes, H2 2016 56 
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 57 
Depression – Pipeline by AB Science SA, H2 2016 58 
Depression – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59 
Depression – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 60 
Depression – Pipeline by Adamed Sp. z o.o., H2 2016 61 
Depression – Pipeline by Addex Therapeutics Ltd, H2 2016 62 
Depression – Pipeline by Aequus Pharmaceuticals Inc., H2 2016 63 
Depression – Pipeline by Alkermes Plc, H2 2016 64 
Depression – Pipeline by Allergan Plc, H2 2016 65 
Depression – Pipeline by Alvogen Korea Co., Ltd., H2 2016 66 
Depression – Pipeline by Amorsa Therapeutics Inc., H2 2016 67 
Depression – Pipeline by Anavex Life Sciences Corp., H2 2016 68 
Depression – Pipeline by Angelini Group, H2 2016 69 
Depression – Pipeline by Angita B.V., H2 2016 70 
Depression – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 71 
Depression – Pipeline by AstraZeneca Plc, H2 2016 72 
Depression – Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 73 
Depression – Pipeline by Axsome Therapeutics Inc, H2 2016 74 
Depression – Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 75 
Depression – Pipeline by BioCrea GmbH, H2 2016 76 
Depression – Pipeline by Biogen Inc, H2 2016 77 
Depression – Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 78 
Depression – Pipeline by BioLite, Inc., H2 2016 79 
Depression – Pipeline by Bionomics Limited, H2 2016 80 
Depression – Pipeline by Boehringer Ingelheim GmbH, H2 2016 81 
Depression – Pipeline by Bristol-Myers Squibb Company, H2 2016 82 
Depression – Pipeline by Calico LLC, H2 2016 83 
Depression – Pipeline by Celon Pharma Sp. z o.o., H2 2016 84 
Depression – Pipeline by Cerecor Inc., H2 2016 85 
Depression – Pipeline by Clera Inc., H2 2016 86 
Depression – Pipeline by D-Pharm Ltd., H2 2016 87 
Depression – Pipeline by Delpor, Inc., H2 2016 88 
Depression – Pipeline by e-Therapeutics Plc, H2 2016 89 
Depression – Pipeline by Eisai Co., Ltd., H2 2016 90 
Depression – Pipeline by Eli Lilly and Company, H2 2016 91 
Depression – Pipeline by Evotec AG, H2 2016 92 
Depression – Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 93 
Depression – Pipeline by GlaxoSmithKline Plc, H2 2016 94 
Depression – Pipeline by GliaCure Inc., H2 2016 95 
Depression – Pipeline by H. Lundbeck A/S, H2 2016 96 
Depression – Pipeline by Heptares Therapeutics Limited, H2 2016 97 
Depression – Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 98 
Depression – Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 99 
Depression – Pipeline by Impel NeuroPharma, Inc., H2 2016 100 
Depression – Pipeline by INSYS Therapeutics, Inc., H2 2016 101 
Depression – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 102 
Depression – Pipeline by Intra-Cellular Therapies, Inc., H2 2016 103 
Depression – Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 104 
Depression – Pipeline by Johnson & Johnson, H2 2016 105 
Depression – Pipeline by KemPharm, Inc., H2 2016 106 
Depression – Pipeline by Lead Discovery Center GmbH, H2 2016 107 
Depression – Pipeline by Les Laboratoires Servier SAS, H2 2016 108 
Depression – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 109 
Depression – Pipeline by Luye Pharma Group Ltd., H2 2016 110 
Depression – Pipeline by Mapi Pharma Ltd., H2 2016 111 
Depression – Pipeline by Mapreg S.A.S., H2 2016 112 
Depression – Pipeline by Meta-IQ ApS, H2 2016 113 
Depression – Pipeline by Methylation Sciences Inc., H2 2016 114 
Depression – Pipeline by miCure Therapeutics Ltd., H2 2016 115 
Depression – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 116 
Depression – Pipeline by Navya Biologicals Pvt Ltd, H2 2016 117 
Depression – Pipeline by Neuralstem, Inc., H2 2016 118 
Depression – Pipeline by Neurocrine Biosciences, Inc., H2 2016 119 
Depression – Pipeline by NeuroNascent, Inc., H2 2016 120 
Depression – Pipeline by NeurOp, Inc, H2 2016 121 
Depression – Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 122 
Depression – Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 123 
Depression – Pipeline by nLife Therapeutics, S.L., H2 2016 124 
Depression – Pipeline by Novartis AG, H2 2016 125 
Depression – Pipeline by Omeros Corporation, H2 2016 126 
Depression – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 127 
Depression – Pipeline by Pfizer Inc., H2 2016 128 
Depression – Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 129 
Depression – Pipeline by Polleo Pharma Limited, H2 2016 130 
Depression – Pipeline by Protagenic Therapeutics Inc., H2 2016 131 
Depression – Pipeline by Relmada Therapeutics, Inc., H2 2016 132 
Depression – Pipeline by Reviva Pharmaceuticals Inc., H2 2016 133 
Depression – Pipeline by Richter Gedeon Nyrt., H2 2016 134 
Depression – Pipeline by Saniona AB, H2 2016 135 
Depression – Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 136 
Depression – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 137 
Depression – Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 138 
Depression – Pipeline by Suven Life Sciences Ltd., H2 2016 139 
Depression – Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 140 
Depression – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 141 
Depression – Pipeline by Tetra Discovery Partners LLC, H2 2016 142 
Depression – Pipeline by Trevena, Inc., H2 2016 143 
Depression – Pipeline by TRImaran Pharma, Inc., H2 2016 144 
Depression – Pipeline by Turing Pharmaceuticals AG , H2 2016 145 
Depression – Pipeline by VistaGen Therapeutics , Inc., H2 2016 146 
Depression – Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016 147 
Depression – Pipeline by Zogenix, Inc., H2 2016 148 
Depression – Pipeline by Zysis Limited, H2 2016 149 
Assessment by Monotherapy Products, H2 2016 150 
Assessment by Combination Products, H2 2016 151 
Number of Products by Stage and Target, H2 2016 153 
Number of Products by Stage and Mechanism of Action, H2 2016 160 
Number of Products by Stage and Route of Administration, H2 2016 167 
Number of Products by Stage and Molecule Type, H2 2016 169 
Depression – Dormant Projects, H2 2016 451 
Depression – Dormant Projects (Contd..1), H2 2016 452 
Depression – Dormant Projects (Contd..2), H2 2016 453 
Depression – Dormant Projects (Contd..3), H2 2016 454 
Depression – Dormant Projects (Contd..4), H2 2016 455 
Depression – Dormant Projects (Contd..5), H2 2016 456 
Depression – Dormant Projects (Contd..6), H2 2016 457 
Depression – Dormant Projects (Contd..7), H2 2016 458 
Depression – Dormant Projects (Contd..8), H2 2016 459 
Depression – Dormant Projects (Contd..9), H2 2016 460 
Depression – Dormant Projects (Contd..10), H2 2016 461 
Depression – Dormant Projects (Contd..11), H2 2016 462 
Depression – Dormant Projects (Contd..12), H2 2016 463 
Depression – Dormant Projects (Contd..13), H2 2016 464 
Depression – Dormant Projects (Contd..14), H2 2016 465 
Depression – Dormant Projects (Contd..15), H2 2016 466 
Depression – Dormant Projects (Contd..16), H2 2016 467 
Depression – Dormant Projects (Contd..17), H2 2016 468 
Depression – Dormant Projects (Contd..18), H2 2016 469 
Depression – Dormant Projects (Contd..19), H2 2016 470 
Depression – Dormant Projects (Contd..20), H2 2016 471 
Depression – Dormant Projects (Contd..21), H2 2016 472 
Depression – Dormant Projects (Contd..22), H2 2016 473 
Depression – Dormant Projects (Contd..23), H2 2016 474 
Depression – Dormant Projects (Contd..24), H2 2016 475 
Depression – Discontinued Products, H2 2016 476 
Depression – Discontinued Products (Contd..1), H2 2016 477 
Depression – Discontinued Products (Contd..2), H2 2016 478 
Depression – Discontinued Products (Contd..3), H2 2016 479 
Depression – Discontinued Products (Contd..4), H2 2016 480 
Depression – Discontinued Products (Contd..5), H2 2016 481 
Depression – Discontinued Products (Contd..6), H2 2016 482 
Depression – Discontinued Products (Contd..7), H2 2016 483

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693292

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.